A Japan, Kwamitin Ba da Shawara kan Covid-19 na Ma’aikatar Kiwon Lafiya ya amince da yin amfani da allurar riga-kafin sabon nau'in kwayar cutar corona (Covid-19) wanda kamfanin harhada magunguna na Amurka, Moderna ya samar ga duk masu shekaru 12 zuwa sama.
A cewar labarin kamfanin dillancin labarai na Kyodo, wanda ya samo asali daga majiyoyin Ma'aikatar Lafiya, ana sa ran samun izinin hukuma daga ma'aikatar ga allurar a wannan watan.
Wannan zai bada damar yin allurar kyauta a wani bangare na shirin riga-kafi na kasa da gwamnati ke gudanarwa.
An ba da izinin hukuma don yin amfani da allurar riga-kafin Covid-19 wanda kamfanin Amurka Pfizer ya samar ga ‘yan shekaru 12 zuwa sama a watan Mayu.
A gefe guda kuma, kwamitin ba da shawara ya kuma amince da wani maganin Covid-19, wanda ya kunshi sinadarai wadanda ake kira "casirivimab" da "Indevimab" da ke ba da kariya kan Covid-19.
Idan an samu izinin hukuma, maganin zai zama magani na 4 da aka amince da shi a Japan kan Covid-19 bayan "Remdesivir", "Steroid dexamethasone" da "Baricitinib."
Maganin ya kunshi sinadiran da ke yakar cutar Covid-19 wadanda ake kira "casirivimab" da "Indevimab", wasu nau'ikan sinadarai ne da aka tsara da ke ganewa da kuma mannewa kan kwayar cutar.
